Please wait...
3
154
Offers Claimed: 105
Downloaded Today: 197
Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:
Yes
100% of Medicare Part D and Medicare Advantage plans cover this drug.It depends. Which coverage stage are you in? Click on a tab below…
FREE – $20
In the Deductible co-pay stage, you are responsible for the full cost of your prescriptions. Your Medicare deductible cannot exceed $360 in 2016.
Here are some ways that may lower the cost of your metoprolol succinate er prescription.
If your Medicare co-pay is higher, you can save money by using a USARx coupon instead.
Commonly reported side effects of metoprolol include: cardiac failure, bradycardia, and hypotension. See below for a comprehensive list of adverse effects.
For the ConsumerApplies to metoprolol: oral capsule extended release, oral tablet, oral tablet extended release
Other dosage forms:
Oral route (Tablet, Extended Release)
Exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred after abrupt cessation of therapy with certain beta-blocking agents. When discontinuing chronic therapy, gradually reduce the dose over a period of 1 to 2 weeks and monitor the patient carefully. If angina markedly worsens or acute coronary insufficiency develops, reinstate administration promptly, at least temporarily, and take other measures appropriate for the management of unstable angina. Warn patients not to interrupt or discontinue therapy without physician advice.
Oral route (Tablet)
Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. The dosage should be gradually reduced over a period of 1 to 2 weeks and the patient should be carefully monitored when discontinuing chronic therapy. If angina markedly worsens or acute coronary insufficiency develops, metoprolol tartrate administration should be reinstated promptly, at least temporarily, and other measures appropriate for the management of unstable angina should be taken. Patients should be warned against interruption or discontinuation of therapy without the physician's advice. Because coronary artery disease is common and may be unrecognized, it may be prudent not to discontinue metoprolol tartrate therapy abruptly even in patients treated only for hypertension.
Along with its needed effects, metoprolol may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor immediately if any of the following side effects occur while taking metoprolol:
More common
Less common
Rare
Incidence not known
Get emergency help immediately if any of the following symptoms of overdose occur while taking metoprolol:
Symptoms of overdose
Some side effects of metoprolol may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Less common
Rare
Incidence not known
For Healthcare Professionals
Applies to metoprolol: compounding powder, injectable solution, oral capsule extended release, oral solution, oral tablet, oral tablet extended release
GeneralThe most common adverse reactions were tiredness, dizziness, depression, shortness of breath, bradycardia, hypotension, diarrhea, pruritus, and rash.
CardiovascularVery common (10% or more): Heart failure (up to 27.5%), hypotension (systolic blood pressure less than 90 mmHg) (up to 27.4%), bradycardia (heart rate less than 40 beats per minute) (up to 15.9%),
Common (1% to 10%): Cold extremities, arterial insufficiency, palpitation, first degree heart block (P-R interval 0.26 seconds or greater), second or third degree heart block, postural disorders
Uncommon (0.1% to 1%): Cardiogenic shock in patients with acute myocardial infarction
Rare (0.01% to 0.1%): Disturbances of cardiac conduction, cardiac arrhythmia
Very rare (less than 0.01%): Intermittent claudication increased
Frequency not reported: Claudication
GastrointestinalCommon (1% to 10%): Diarrhea, nausea, dry mouth, gastric pain, constipation, flatulence, heartburn, abdominal pain, vomiting
Frequency not reported: Retroperitoneal fibrosis
OtherCommon (1% to 10%): Tiredness, peripheral edema, accident and/or injury, death, fatigue
Uncommon (0.1% to 1%): Edema, precordial pain
Frequency not reported: Lactic dehydrogenase elevated
Postmarketing reports: Chest pain
Nervous systemCommon (1% to 10%): Dizziness, vertigo, stroke, headache
Uncommon (0.1% to 1%): Paresthesia, somnolence, impaired concentration
Rare (0.01% to 0.1%): Alertness decreased
Very rare (less than 0.01%): Amnesia/memory impairment, tinnitus, taste disturbance
Frequency not reported: Short-term memory loss
Postmarketing reports: Syncope
RespiratoryCommon (1% to 10%): Shortness of breath, wheezing, dyspnea
Rare (less than 0.1%): Rhinitis
DermatologicCommon (1% to 10%): Pruritus, rash
Uncommon (0.1% to 1%): Sweating increased
Rare (0.01% to 0.1%): Loss of hair
Very rare (less than 0.01%): Photosensitivity reactions, psoriasis aggravated, gangrene in patients with preexisting severe peripheral circulatory disorders, hyperhidrosis, alopecia
PsychiatricCommon (1% to 10%): Depression
Uncommon (0.1% to 1%): Insomnia, nightmare
Rare (0.01% to 0.1%): Nervousness, anxiety
Very rare (less than 0.01%): Confusion, hallucination, personality disorder, disturbances of libido
Frequency not reported: Sleep disturbance
MusculoskeletalUncommon (0.1% to 1%): Muscle cramps
Very rare (less than 0.01%): Arthralgia, arthritis
Frequency not reported: Musculoskeletal pain
MetabolicUncommon (0.1% to 1%): Weight gain
Frequency not reported: Unstable diabetes
Postmarketing reports: Blood triglycerides increased, high density lipoprotein (HDL) decreased
OcularRare (less than 0.1%): Visual disturbance, dry and/or irritated eyes, conjunctivitis
Frequency not reported: Blurred vision
HepaticRare (0.01% to 0.1%): Liver function test abnormalities
Very rare (less than 0.01%): Hepatitis
Frequency not reported: Transaminase elevated, alkaline phosphatase elevated
Postmarketing reports: Jaundice, non-specific hepatic dysfunction
GenitourinaryRare (0.01% to 0.1%): Impotence/sexual dysfunction
Very rare (less than 0.01%): Peyronie's disease
ImmunologicRare (less than 0.1%): Positive antinuclear antibodies
HematologicVery rare (less than 0.01%): Thrombocytopenia
Frequency not reported: Agranulocytosis
Medically reviewed by USARx EDITORIAL TEAM Last updated on 1/3/2022.
Source: Drugs.com Metoprolol Succinate Er (www.drugs.com/metoprolol.html).
March 2, 2020
August 31, 2020
July 1, 2020
July 2, 2020
August 4, 2022
August 4, 2022